Work

Effect of erythropoietin-stimulating agent use on belzutifan antitumor activity in patients with VHL disease–associated renal cell carcinoma: Post hoc analysis of the LITESPARK-004 study.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.4_suppl.3

Authors: Benjamin L. Maughan, Ramaprasad Srinivasan, Othon Iliopoulos, Ane Bundsbæk Bøndergaard Iversen, Vivek Narayan, Stephane Oudard, Tobias Else, Jodi K. Maranchie, Katy Beckermann, Wei Fu, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, Eric Jonasch

Institutions: University of Utah, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Harvard University, Massachusetts General Hospital, Aarhus University Hospital, University of Pennsylvania, Université Paris Cité, University of Michigan, University of Pittsburgh, Vanderbilt University Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4391303493

Cites:

Cited by: 8

Related to: 10